Leadership

Bernd Brust brings more than 30 years of global leadership experience in life sciences and scientific instrumentation, with a focus on commercial operations, strategic growth, and innovation. Mr. Brust was appointed CEO and a Board Member of Maravai LifeSciences in June 2025.

Bernd brings more than 30 years of leadership experience in the life sciences industry. Previously, Bernd served as Executive Chairman and CEO of Antylia Scientific, a global provider of tools and solutions for diagnostic testing, sample preparation, biological monitoring, and environmental analysis. The company was a portfolio investment of private equity firm GTCR, which acquired Antylia in 2019 and sold it to Brookfield Asset Management for approximately $1.3 billion in 2025.

Before that, he was President and CEO of Qualicaps, a global provider of capsule manufacturing and processing equipment for the pharmaceutical industry, which was acquired by Mitsubishi Chemical Holdings in 2013.

Earlier in his career, Mr. Brust was Chief Commercial Operations Officer at Life Technologies Corporation, responsible for a $3.5 billion global business. He also held senior leadership positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems, where he gained broad experience across operational, sales, and business development functions.

Raj Asarpota brings nearly 30 years of global executive leadership experience, including more than a decade as CFO of public and private life sciences and medical device companies. He was appointed Executive Vice President and Chief Financial Officer of Maravai LifeSciences in June 2025.

Raj joins Maravai with a strong track record of driving performance, advancing strategic initiatives, and scaling operations through organic growth and strategic acquisitions. Most recently, he served as EVP and CFO of Augmedics, a medical device company that develops augmented reality surgical navigation systems, with a focus on spine surgery, where he scaled commercial operations, raised capital, and led a strategic IP acquisition.

Previously, he was EVP and CFO of NuVasive, where he helped increase market capitalization by $1.2 billion and delivered significant margin expansion. He also served as CFO and COO of Cole-Parmer, where he led the company’s carve-out from Thermo Fisher Scientific. His earlier career includes key financial and operational leadership roles at Questcor Pharmaceuticals, Life Technologies, and GE Healthcare.

In his role at Maravai, Raj oversees the company’s global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology functions.

Mr. Asarpota holds an MBA from Marquette University and a Bachelor of Commerce from the University of Mumbai.

Pete Leddy has over 30 years of experience leading growth and change across a wide variety of businesses, and specifically in scaling global healthcare companies. Throughout 2022, Pete worked as a consultant to Maravai on a number of issues related to organizational design, compensation and retention before joining the Company as CAO. Previously, Pete served as Chief Human Resources Officer at Berkeley Lights, Chief People Officer at dosist, Executive Vice President, Global Human Resources and Corporate Integrity at Nuvasive and Chief Human Resources Officer at Life Technologies and Invitrogen. Earlier in his career he held a variety of executive and human resource positions at Dell, Promus Hotel Corp. and PepsiCo. He received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. degrees in industrial/organizational psychology from the Illinois Institute of Technology.

Becky Buzzeo has more than 20 years of commercial leadership experience. Before joining Maravai, in October of 2022, she was the Vice President and General Manager, Advanced Therapies, at Thermo Fisher Scientific, where she oversaw CDMO services for plasmid DNA, cell therapy and mRNA. Prior to that, Mrs. Buzzeo led commercial operations at Brammer Bio and held commercial roles of increasing responsibility at Patheon Biologics and Life Technologies, before its acquisition by Thermo Fisher in 2014. Mrs. Buzzeo holds a B.S. in biology from Slippery Rock University of Pennsylvania.

Christine Dolan has served as the Chief Operating Officer of Maravai LifeSciences’ Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles including Senior Vice President of Product Development, VP of Global Operations and VPGM of Development and Analytical Services at Catalent Pharma Solutions. Prior to joining Catalent Pharma Solutions, she was Director of Nuclear Operations and Global Quality Control at GE Healthcare and Amersham Health. Dolan holds a B.S. in biology from Lenoir-Rhyne College.

Kurt Oreshack joined Maravai LifeSciences as General Counsel in November 2020. Prior to joining Maravai, Mr. Oreshack was a partner at Breakwater Law Group, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, he was the General Counsel of Human Longevity, and previously practiced law individually and as General Counsel in Residence at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian. Mr. Oreshack received a J.D. from the University of Notre Dame Law School and a B.A. from Loyola University Chicago. He is a member of the State Bar of California.

Chanfeng brings over 20 years of experience of nucleotide and modified nucleotides used in Sequencing and Synthetic Genomics fields. She was the Chief Executive Officer and Co-founder of MyChem LLC (acquired by TriLink), a company that specialized in making synthetic ultra-pure nucleotides to customers in the diagnostics, pharmaceutics, genomics and research markets. Prior to MyChem, Chanfeng was one of the first employees at Illumina where she was a Staff Scientist and Project Leader. While there, she developed the chemistry of attaching modified oligonucleotides to bead surfaces for BeadChip products. Chanfeng received her PhD in Chemistry from SUNY at Buffalo, and a B.Sc with honors in Petroleum Chemical Engineering from East China University of Science and Technology.

Chad Decker, Senior Vice President, Sales, TriLink and Alphazyme has over 20 years of experience in commercial and operational leadership roles across biotech, healthcare, life science, and diagnostics industries, Mr. Decker co-founded Alphazyme in 2018 as Chief Operating Officer and has built global organizations from the ground up, efficiently integrated new acquisitions, developed strategies for aligning multiple business units and launching disruptive technologies, and had full P&L oversight. Prior to founding Alphazyme, Mr. Decker served as Chief Commercial Officer of TwinStrand Biosciences after heading commercial operations for Quad Technologies, overseeing their successful exit to Bio-Techne. Previously, he led the Qiagen Custom and OEM businesses as their Vice President of Sales, and served in roles of increasing responsibility at ThermoFisher Scientific, ultimately leading the global healthcare sourcing initiative worth over $100 million.

Kevin Lynch has more than 30 years of experience in the life sciences industry. Before joining Maravai in 2023, he was the Head of Operations for Millipore Sigma’s viral and gene therapies business, leading the CDMO clinical and commercial production. Prior to that, Kevin served in sales, manufacturing, operations, and business leader roles at Sartorius Stedim Biotech, Shire Pharmaceuticals, Genzyme Corporation, and Cambridge Biotech. He received his bachelor’s in biology from the University of Vermont. Kevin is a collaborative leader with extensive knowledge of biopharmaceutical processes, expertise in operational excellence, and a deep commitment to continuous process improvement, compliance, and unparalleled customer experience.

Elie Chaaya has more than 20 years of manufacturing and Engineering leadership experience. Before joining Maravai, in March of 2023, Elie created and led the R&D technical Operations team that managed all CMC and tech transfer activities for all small molecule and Antibody drug conjugation at ABBVIE, before transitioning to small molecule commercial manufacturing director role. Prior to that, Elie spent 10 years at Schering-Plough and Merck in various roles, starting as a Plant engineer and progressing into Process engineering and Process Analytical technology. Elie holds a bachelor’s and master’s degree in chemical engineering from New Jersey College of Engineering (NJIT).

Davide De Lucrezia is a synthetic biologist by training with a passion for bridging biology and computer science. He is co-founder and General Manager of Officinae Bio, now part of Maravai Life Sciences. Over the years, he has led multiple biotech ventures, focusing on innovation at the intersection between artificial intelligence and synthetic biology. His mission is to empower biologists to reprogram biology through smarter tools and streamlined workflows

Andrew Murphy is responsible for all site operations including integrating business processes, regulatory compliance, information technology, and business continuity for Glen Research, part of Maravai LifeSciences. He brings over thirty years of experience in chemistry and biotechnology manufacturing, operations management, product development, and quality management. He has held key leadership roles directly supporting Research and Development, Manufacturing, Quality Control, and Quality Assurance. He holds an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Chemistry from University of Maryland.

Judy Solecki is an accomplished HR professional who has focused her career on developing talent and capabilities to help organizations reach their strategic goals. She has passion for the life sciences industry and has a significant breadth of experience, having spent much of her career working with teams across a variety of countries, industries, and areas of HR. Prior to joining Maravai she was at Illumina where she led HR for the Commercial and Marketing organizations. Prior to that, she held roles of increasing responsibility at BD (Becton Dickinson), Cytori, Invitrogen (now part of Thermo Fisher Scientific), Conexant Systems, and NASA. Judy has a bachelor’s in psychology from Michigan State, and completed both her master’s and her PhD in industrial organizational psychology at Rice University.